2018
DOI: 10.9734/ijbcrr/2018/44353
|View full text |Cite
|
Sign up to set email alerts
|

Subchronic Toxicity Study of the Extract of Sacoglottis gabonensis (Baille) Urban (Humiriaceae) in Wistar Rats

Abstract: Introduction: Sacoglottis gabonensis (Baille) Urban (Humiriaceae) is a medicinal plant used in the treatment of Buruli ulcer in Ivory Coast. To ensure its effect over a long period of use, the subchronic toxicity of the total aqueous extract of S. gabonensis stem bark (ETASg) in rats was evaluated. Methods: 80 rats were homogeneously distributed in 4 lots of 20 rats each, including 10 males and 10 females. ETASg was administered daily orally for 90 days for 2 mL/100 g body weight (b.w.) rats at doses of 3.5; 3… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

1
0
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 5 publications
1
0
0
Order By: Relevance
“…Otherwise, the reversibility study of the observed effects showed that the macroscopic and microscopic liver abnormalities disappeared after 30 days of stopping the administration of ETASg at 350 mg/kg b. w. This result attested to that of the study of reversibility observed during biochimical analysis. In this study, the increase of ALAT due to ETASg at the dose of 350 mg/kg b. w. was moderate and reversible (Otis et al, 2018). These results suggest that ETASg would not disrupt liver structure and retain the architecture of liver tissue when administered with the therapeutic dose of 3.5 mg/kg b. w. orally for 90 days.…”
Section: Discussionsupporting
confidence: 48%
“…Otherwise, the reversibility study of the observed effects showed that the macroscopic and microscopic liver abnormalities disappeared after 30 days of stopping the administration of ETASg at 350 mg/kg b. w. This result attested to that of the study of reversibility observed during biochimical analysis. In this study, the increase of ALAT due to ETASg at the dose of 350 mg/kg b. w. was moderate and reversible (Otis et al, 2018). These results suggest that ETASg would not disrupt liver structure and retain the architecture of liver tissue when administered with the therapeutic dose of 3.5 mg/kg b. w. orally for 90 days.…”
Section: Discussionsupporting
confidence: 48%